AU2019297523B2 - Triazole glycolate oxidase inhibitors - Google Patents
Triazole glycolate oxidase inhibitors Download PDFInfo
- Publication number
- AU2019297523B2 AU2019297523B2 AU2019297523A AU2019297523A AU2019297523B2 AU 2019297523 B2 AU2019297523 B2 AU 2019297523B2 AU 2019297523 A AU2019297523 A AU 2019297523A AU 2019297523 A AU2019297523 A AU 2019297523A AU 2019297523 B2 AU2019297523 B2 AU 2019297523B2
- Authority
- AU
- Australia
- Prior art keywords
- triazole
- compound
- alkyl
- pharmaceutically acceptable
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US62/694,918 | 2018-07-06 | ||
| US201962827573P | 2019-04-01 | 2019-04-01 | |
| US62/827,573 | 2019-04-01 | ||
| PCT/US2019/040690 WO2020010309A1 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019297523A1 AU2019297523A1 (en) | 2021-02-25 |
| AU2019297523B2 true AU2019297523B2 (en) | 2025-04-17 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019297523A Active AU2019297523B2 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11401246B2 (https=) |
| EP (1) | EP3817816A1 (https=) |
| JP (1) | JP7348705B2 (https=) |
| KR (1) | KR102865323B1 (https=) |
| CN (1) | CN112399873B (https=) |
| AU (1) | AU2019297523B2 (https=) |
| BR (1) | BR112021000050A2 (https=) |
| CO (1) | CO2021001277A2 (https=) |
| IL (1) | IL279952B2 (https=) |
| MX (1) | MX2021000051A (https=) |
| PE (1) | PE20210859A1 (https=) |
| SA (1) | SA521420951B1 (https=) |
| SG (1) | SG11202012930RA (https=) |
| WO (1) | WO2020010309A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021000050A2 (pt) | 2018-07-06 | 2021-04-06 | Orfan Biotech Inc. | Inibidores de triazol glicolato oxidase |
| AU2020376792B2 (en) | 2019-11-01 | 2025-10-02 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4087836B1 (en) * | 2020-01-08 | 2025-10-08 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| JP2024538054A (ja) * | 2021-10-11 | 2024-10-18 | カンテロ セラピューティクス，インコーポレイティド | 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸 |
| WO2024109917A1 (zh) * | 2022-11-25 | 2024-05-30 | 西藏海思科制药有限公司 | 一种三唑衍生物及其在医药上的应用 |
| WO2024212137A1 (en) * | 2023-04-12 | 2024-10-17 | Cantero Therapeutics, Inc. | Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100266A1 (en) * | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| WO2019133770A2 (en) * | 2017-12-29 | 2019-07-04 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (ja) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | ベンゾピラノトリアゾ−ル誘導体 |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| CN101307307A (zh) * | 2008-07-11 | 2008-11-19 | 华东理工大学 | 一种乙醇酸氧化酶制剂、制备方法及应用 |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| JP5455279B1 (ja) | 2012-10-25 | 2014-03-26 | アサヒグループホールディングス株式会社 | ラテックスの増産方法 |
| WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (fr) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | Methode et composition pour ameliorer la productivite de plantes non legumineuses |
| JP5866035B1 (ja) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | 有効分げつ促進方法 |
| JP7148241B2 (ja) | 2015-03-19 | 2022-10-05 | 三菱商事ライフサイエンス株式会社 | 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物 |
| EP3731840A4 (en) | 2017-12-29 | 2021-09-15 | Orfan Biotech Inc. | NADPH OXIDASE INHIBITORS AND THEIR USE |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| BR112021000050A2 (pt) | 2018-07-06 | 2021-04-06 | Orfan Biotech Inc. | Inibidores de triazol glicolato oxidase |
| CA3143334A1 (en) | 2019-06-19 | 2020-12-24 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
-
2019
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/pt unknown
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 IL IL279952A patent/IL279952B2/en unknown
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/es unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873B/zh active Active
- 2019-07-05 AU AU2019297523A patent/AU2019297523B2/en active Active
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en not_active Ceased
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/ja active Active
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/es unknown
- 2019-07-05 KR KR1020217003486A patent/KR102865323B1/ko active Active
-
2021
- 2021-01-03 SA SA521420951A patent/SA521420951B1/ar unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/es unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100266A1 (en) * | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| WO2019133770A2 (en) * | 2017-12-29 | 2019-07-04 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE REGISTRY, CHEMICAL ABSTRACTS SERVICE, 21 August 2017, CAS registry no. 2117454-53-0, Compound name: 5-(3-bromophenoxy)-1-methyl-1 H-1,2,3-Triazole-4-carboxylic acid * |
| DATABASE REGISTRY, CHEMICAL ABSTRACTS SERVICE, 28 July 2017, retrieved from STN Database CAS registry no. 2104463-72-9, chemical name: 5-[3-Methyl-4-(1-methylethyl)phenoxy]-1H-1,2,3-triazole-4-carboxylic acid * |
| DATABASE REGISTRY, CHEMICAL ABSTRACTS SERVICE, 29 August 2017, CAS registry no. 2122068-03-3, chemical name: 5-(4-bromophenoxy)-1-methyl-1H-1,2,3-Triazole-4-carboxylic acid * |
| DEREK R. BUCKLE ET AL: "Studies on v-triazoles. 7. Antiallergic 9-oxo-1H,9H-benzopyrano[2,3-d]-v-triazoles", JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 2, 1 February 1983 (1983-02-01), US, pages 251 - 254, DOI: 10.1021/jm00356a025 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL279952A (en) | 2021-03-01 |
| EP3817816A1 (en) | 2021-05-12 |
| CN112399873B (zh) | 2024-10-25 |
| BR112021000050A2 (pt) | 2021-04-06 |
| SG11202012930RA (en) | 2021-01-28 |
| PE20210859A1 (es) | 2021-05-18 |
| KR20210041564A (ko) | 2021-04-15 |
| JP7348705B2 (ja) | 2023-09-21 |
| WO2020010309A9 (en) | 2020-01-30 |
| US20230143491A1 (en) | 2023-05-11 |
| US20210403439A1 (en) | 2021-12-30 |
| KR102865323B1 (ko) | 2025-09-26 |
| US11401246B2 (en) | 2022-08-02 |
| WO2020010309A1 (en) | 2020-01-09 |
| JP2021530560A (ja) | 2021-11-11 |
| MX2021000051A (es) | 2021-03-25 |
| CN112399873A (zh) | 2021-02-23 |
| AU2019297523A1 (en) | 2021-02-25 |
| IL279952B1 (en) | 2024-07-01 |
| CA3104529A1 (en) | 2020-01-09 |
| IL279952B2 (en) | 2024-11-01 |
| CO2021001277A2 (es) | 2021-04-30 |
| SA521420951B1 (ar) | 2024-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019297523B2 (en) | Triazole glycolate oxidase inhibitors | |
| US12133853B2 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| US10822326B2 (en) | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | |
| TWI617559B (zh) | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 | |
| WO2023062575A1 (en) | Cyclic vinyl sulfone compounds as wrn inhibitors | |
| WO2007037534A1 (ja) | ２－へテロアリール置換インドール誘導体 | |
| US20230078764A1 (en) | Compounds and uses thereof | |
| EA030410B1 (ru) | Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
| EP3585772B1 (en) | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | |
| US20210171503A1 (en) | Glycolate oxidase inhibitors and use thereof | |
| AU2019291490B2 (en) | Cyanotriazole compounds and uses thereof | |
| CN109641909B (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
| CN110662539A (zh) | 三取代的苯并三唑衍生物作为二氢乳清酸加氧酶抑制剂的使用方法 | |
| US20200055839A1 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| CA3104529C (en) | Triazole glycolate oxidase inhibitors | |
| US20230295110A1 (en) | Phd inhibitor compounds, compositions, and methods of use | |
| NZ746586A (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| NZ746586B2 (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| HK40002867A (en) | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | |
| HK1217701B (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| HK1217701A1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: CANTERO THERAPEUTICS, INC. Free format text: FORMER NAME(S): ORFAN BIOTECH INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |